Nabriva Therapeutics to Participate in Upcoming Virtual Investor Conferences in January
January 05, 2021 16:01 ET
|
Nabriva Therapeutics US, Inc
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of...
Nabriva Therapeutics Announces Pricing of $15 Million Public Offering
December 10, 2020 23:18 ET
|
Nabriva Therapeutics US, Inc
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of...
Nabriva Therapeutics Announces Proposed Public Offering
December 10, 2020 16:01 ET
|
Nabriva Therapeutics US, Inc
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of...
Nabriva Therapeutics and Sinovant Sciences Restructure License Agreement for XENLETA for Community-Acquired Bacterial Pneumonia in China
December 07, 2020 07:00 ET
|
Nabriva Therapeutics US, Inc
-Amended agreement encompasses enhanced manufacturing collaboration and regulatory support -Accelerates milestone payments to Nabriva, including fourth quarter 2020 payment of $1 million DUBLIN,...
Nabriva Therapeutics Announces Date of 1-for-10 Reverse Stock Split
December 02, 2020 08:00 ET
|
Nabriva Therapeutics US, Inc
DUBLIN, Ireland, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
Nabriva Therapeutics to Participate in Upcoming Virtual Investor Conferences
November 12, 2020 07:01 ET
|
Nabriva Therapeutics US, Inc
DUBLIN, Ireland, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
Nabriva Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
November 05, 2020 16:01 ET
|
Nabriva Therapeutics US, Inc
-Relaunch of Xenleta® and Sivextro® commenced in late September- - Type A Meeting with FDA for Contepo™ held on October 30th - -Conference call today at 4:30 p.m. Eastern Time- DUBLIN, Ireland,...
Nabriva Therapeutics to Report Third Quarter 2020 Financial Results on November 5, 2020
November 02, 2020 16:01 ET
|
Nabriva Therapeutics US, Inc
DUBLIN, Ireland, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
Nabriva’s XENLETA Demonstrates High Efficacy in Patients of Advanced Age with Community-Acquired Bacterial Pneumonia (CABP)
October 13, 2020 07:00 ET
|
Nabriva Therapeutics US, Inc
-- Findings underscore potential of XENLETA as a first-in-class pleuromutilin antibiotic for the IV and oral treatment of CABP in adults, including older patients with comorbidities who are at risk of...
Nabriva Therapeutics Granted New Technology Add-On Payment for XENLETA® (lefamulin) and CONTEPO™ (fosfomycin) by Centers for Medicare & Medicaid Services
September 10, 2020 08:39 ET
|
Nabriva Therapeutics US, Inc
-NTAP designation highlights need for novel antibiotics to fight drug-resistant infections and advance antimicrobial stewardship -CONTEPO first Qualified Infectious Disease Product to receive NTAP...